{"id":963800,"date":"2026-05-17T16:03:10","date_gmt":"2026-05-17T20:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/"},"modified":"2026-05-17T16:03:10","modified_gmt":"2026-05-17T20:03:10","slug":"design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/","title":{"rendered":"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CARLSBAD, Calif., May  17, 2026  (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1\/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich\u2019s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.<\/p>\n<p>A live webcast of the presentation will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n7u4wow4Vz_0XIUBw6S7bkYCE6mlrMiQykCUn1-p5qy2uDAVUoGuHoqmrYRSLszvzxX6yhSPpxcoQ6DfT2qmIBeoEQVXGYw179yddF73IMPrU-yfPw8VEd88kaFCAqwJrkMBJYHQlG8AvAOdlH2B_g==\" rel=\"nofollow\" target=\"_blank\">here<\/a> and in the investors section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oaLwkID2-zYwtM1Og91LzsO6iM4HJuTnKfz50G7PNfflfUenA0InuoS2OUiyMsY9CR63NqR6i3yEd3F1OH0hF5ypKegNqEBe9RvWktiQtNw=\" rel=\"nofollow\" target=\"_blank\">www.designtx.com<\/a>. The webcast will be archived for at least 30 days following the presentation.<\/p>\n<p>\n        <strong>About Design Therapeutics<\/strong><br \/>\n        <br \/>Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC<sup>\u00ae<\/sup> gene targeted chimera small molecules. The company\u2019s GeneTAC<sup>\u00ae<\/sup> molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC<sup>\u00ae<\/sup> programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington\u2019s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Renee Leck, THRUST <br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xp_jx-ilB1QX5yotokFV8grZ2vXotNcoicRAYtVNuuJRE3gaknck_nub89sFkiLq8SWZoUv9UgTd-CEJqMi1qWGyzGFdcLZ-nMKhcfJQUl8=\" rel=\"nofollow\" target=\"_blank\">renee@thrustsc.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGZiZTUxYzYtMWZkMC00YmRlLWEzMDAtNTRlZTVhODAwMGQwLTEyMTgzOTItMjAyNi0wNS0xNy1lbg==\/tiny\/Design-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1\/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich\u2019s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company\u2019s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design Therapeutics Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u00ae gene targeted chimera small molecules. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963800","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1\/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich\u2019s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company\u2019s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design Therapeutics Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u00ae gene targeted chimera small molecules. &hellip; Continue reading &quot;Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-17T20:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026\",\"datePublished\":\"2026-05-17T20:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/\"},\"wordCount\":229,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/\",\"name\":\"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=\",\"datePublished\":\"2026-05-17T20:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/","og_locale":"en_US","og_type":"article","og_title":"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026 - Market Newsdesk","og_description":"CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1\/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich\u2019s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company\u2019s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design Therapeutics Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u00ae gene targeted chimera small molecules. &hellip; Continue reading \"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-17T20:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026","datePublished":"2026-05-17T20:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/"},"wordCount":229,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/","name":"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=","datePublished":"2026-05-17T20:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTc5NyM3NjA3NTg2IzIyMDY4Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963800"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963800\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}